Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 22, Issue 11, 2004, Pages 2177-2183

  Stebbing, Justin ^a   Gazzard, Brian ^a   Mandalia, Sundhiya ^a   Teague, Alastair ^a   Waterston, Ashita ^a   Marvin, Vanessa ^a   Nelson, Mark ^a   Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD19 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; B LYMPHOCYTE; CANCER RISK; COHORT ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LYMPHOCYTE; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; T LYMPHOCYTE; ADULT; B CELL LYMPHOMA; BLOOD; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; MALE; METABOLISM; METHODOLOGY; PROSPECTIVE STUDY; RISK; STATISTICAL MODEL;

ADULT; ANTIGENS, CD19; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV-1; HUMANS; KILLER CELLS, NATURAL; LINEAR MODELS; LYMPHOCYTE SUBSETS; LYMPHOMA, AIDS-RELATED; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK;

EID: 2942668445     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.097     Document Type: Article

References (53)

1. Ziegler JL, Drew WL, Miner RC, et al: Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet 2:631-633, 1982
2. Ziegler JL, Beckstead JA, Volberding PA, et al: Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 311:565-570, 1984
3. Ziegler JL, Bragg K, Abrams D, et al: High-grade non-Hodgkin's lymphoma in patients with AIDS. Ann N Y Acad Sci 437:412-419, 1984
4. Stebbing J, Bower M: What can oncologists learn from HIV? Lancet Oncol 4:438-445, 2003
5. Ledergerber B, Telenti A, Egger M: Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study. BMJ 319: 23-24, 1999
6. Ratner L, Lee J, Tang S, et al: Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19:2171-2178, 2001
7. Otieno MW, Banura C, Katongole-Mbidde E. et al: Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa. J Natl Cancer Inst 94:718-732, 2002
8. Thirlwell C, Sarker D. Stebbing J, et al: Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma 4:86-92, 2003
9. Bower M, Fife K, Sullivan A, et al: Treatment outcome in presumed and confirmed AIDS-related primary cerebral lymphoma. Eur J Cancer 35:601-604, 1999
10. Matthews GV, Bower M, Mandalia S, et al: Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 96:2730-2734. 2000
11. Palella FJ Jr, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860, 1998
12. Portsmouth S, Stebbing J, Gazzard B: Current treatment of HIV infection. Curr Top Med Chem 3:1458-1466, 2003
13. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92:1823-1830, 2000
14. Bower M, Fox P, Fife K, et al: Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 13: 2105-2111, 1999
15. Langford A, Ruf B, Kunze R, et al: Regression of oral Kaposi's sarcoma in a case of AIDS on zidovudine (AZT). Br J Dermatol 120:709-713, 1989
16. Cattelan AM, Calabro ML, Aversa SM, et al: Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: Biological correlates of clinical outcome. Eur J Cancer 35:1809-1815, 1999
17. Murdaca G, Campelli A, Setti M. et al: Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. AIDS 16:304-305, 2002
18. Stebbing J, Portsmouth S, Gazzard B: How does HAART lead to the resolution of Kaposi's sarcoma? J Antimicrob Chemother 51: 1095-1098, 2003
19. Stebbing J, Gazzard B, Newsom-Davis T, et al: Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. Int J Cancer 108:473-474, 2004
20. Stebbing J, Gazzard B, Flore O, et al: Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma. AIDS 17: 1998-2000, 2003
21. Portsmouth S, Stebbing J, Gill J, et al: A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 17:F17-F22, 2003
22. Lebbe C, Blum L, Pellet C, et al: Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 12:F45-F49, 1998
23. Pati S, Pelser CB, Dufraine J, et al: Antitumorigenic effects of HIV protease inhibitor ritonavir: Inhibition of Kaposi sarcoma. Blood 99:3771-3779, 2002
24. Sgadari C, Barillari G, Toschi E, et al: HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8:225-232, 2002
25. Stebbing J, Portsmouth S, Nelson M, et al: The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma. Int J Cancer 108:631-633, 2004
26. BHIVA Writing Committee, BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 1:76-101, 2000
27. BHIVA Writing Committee, BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2:276-313, 2001
28. Yeni PG, Hammer SM, Carpenter CC, et al: Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288: 222-235, 2002
29. Neider JA, Wedderburn RW: Generalised linear models. J Royal Stat Soc 135:370-384, 1972
30. Parkin DM, Garcia-Giannoli H, Raphael M, et al: Non-Hodgkin lymphoma in Uganda: A case-control study. AIDS 14:2929-2936, 2000
31. Sitas F, Pacella-Norman R, Carrara H, et al: The spectrum of HIV-1 related cancers in South Africa. Int J Cancer 88:489492, 2000
32. Thomas JO: Acquired immunodeficiency syndrome-associated cancers in Sub-Saharan Africa. Semin Oncol 28:198-206, 2001
33. Martinez E, Arnaiz JA, Podzamczer D, et al: Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 349:1036-1046, 2003
34. Shafer RW, Smeaton LM, Robbins GK, et al: Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349:2304-2315, 2003
35. Amyes E, Hatten C, Montamat-Sicotte D, et al: Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 198:903-911, 2003
36. Fu Z, Cannon MJ: Functional analysis of the CD4(+) T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression. J Virol 74: 6675-6679, 2000
37. Yu Q, Gu JX, Kovacs C, et al: Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. J Immunol 170:1797-1805, 2003
38. Macsween KF, Crawford DH: Epstein-Barr virus-recent advances. Lancet Infect Dis 3:131-140, 2003
39. Rickinson AB, Moss DJ: Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15:405-431, 1997
40. Ling PD, Vilchez RA, Keitel WA, et al: Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 37:1244-1249, 2003
41. Chakrabarti S, Milligan DW, Pillay D. et al: Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 102:839-842, 2003
42. Pollock BH, Jenson HB, Leach CT, et al: Risk factors for pediatric human immunodeficiency virus-related malignancy. JAMA 289: 2393-2399, 2003
43. Pido-Lopez J, Burton C, Hardy G, et al: Thymic output during initial highly active antiretroviral therapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune). AIDS Res Hum Retroviruses 19:103-109, 2003
44. Andrew D, Aspinall R: II-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice. J Immunol 166:1524-1530, 2001
45. Sitas F, Carrara H, Beral V, et al: Antibodies against Human Herpesvirus 8 in Black South African Patients with Cancer. N Engl J Med 340:1863-1871, 1999
46. Stebbing J, Portsmouth S. Bower M: Insights into the molecular biology and sero-epidemiology of Kaposi's sarcoma. Curr Opin Infect Dis 16:25-31, 2003
47. Mocroft A, Katlama C, Johnson AM, et al: AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 356:291-296, 2000
48. Herberman RB, Nunn ME, Holden HT, et al: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 16:230-239, 1975
49. Becker S, Kiessling R, Lee N, et al: Modulation of sensitivity to natural killer cell lysis after in vitro explantation of a mouse lymphoma. J Natl Cancer Inst 61:1495-1498, 1978
50. Stebbing J, Gazzard B: Stemming the HIV epidemic: Prevention and therapy go hand in hand. J HIV Ther 8:51-54, 2003
51. Mbanya DN, Minkoulou EM, Kaptue LN: HIV-1 infection in adults with haematological malignancies in Yaounde, Cameroon. West Afr J Med 21:183-184, 2002
52. Mbulaiteye SM, Parkin DM, Rabkin CS: Epidemiology of AIDS-related malignancies an international perspective. Hematol Oncol Clin North Am 17:673-696, 2003
53. Dal Maso L, Franceschi S: Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 4:110-119, 2003